Molecular advances toward the understanding of the patho-biology of idiopathic myelofibrosis

Current Immunology Reviews

Volumn 2, Issue 2, 2006, Pages 169-186

  Migliaccio, Anna Rita ^a,c   Vannucchi, Alessandro Maria ^b   Migliaccio, Giovanni ^a   Hoffman, Ronald ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Animal models; GATA 1; Idiopathic myelofibrosis; Megakaryocytes; Thrombopoietin

Indexed keywords

ACUTE LEUKEMIA; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CELL TRANSPORT; CLINICAL FEATURE; EXTRAMEDULLARY HEMATOPOIESIS; GENETIC DISORDER; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HYPERPLASIA; MEGAKARYOCYTE; MICROENVIRONMENT; MOLECULAR INTERACTION; MOUSE; MUTAGENESIS; MYELOID METAPLASIA; MYELOPHTHISIC ANEMIA; MYELOPROLIFERATIVE DISORDER; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOSCLEROSIS; PATHOPHYSIOLOGY; PHILADELPHIA 1 CHROMOSOME; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; SPLENOMEGALY; STEM CELL;

EID: 33745847147     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339506776842999     Document Type: Review

References (150)

1. Hoffman R, Ravandi-Kashani F. Myelofibrosis with myeloid metaplasia. In: Hematology: Basic Principles and Practice. (Ed. R. Hoffman, E. Benz Jr., S. Shattil, B. Furie, HJ Cohen, L. Silberstein, P. McGlave). Churchill Livingstone, New York, 4th Edition 2005; pp. 1255-1276.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N EngI J Med 2000; 342: 1255-1265.
3. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954-2970.
4. Thiele J, Pierre R, Imbert M, Vardiman JW, Brunning RD, Glandrin G. Chronic idiopathic myelofibrosis in World Health Organization of Tumors of Hematopoietic and Lymphoid Tissues. (Ed. Jaffe ES, Harris N, Stan N, Vardiman JW). IARC Press, Washington, DC. 2001, pp. 35-38.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Cancer Genome Project Lancet 2005; 365: 1054-1061.
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
8. Kralovics P, Passamonti F, Buser AS, et al. A Gain of function Mutation of Jak2 in myeloproliferative Disorders. N Engl J Med 2005; 352: 1779-1790.
9. Ihle J.N. Cytokine receptor signaling. Nature 1995; 377: 591-594.
10. Drachman JG, Sabath DF, Fox NE, Kaushansky K. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 1987; 89:483-492.
11. Kaushansky K. On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense. Blood 2005; 105: 4187-4190.
12. Zucker-Franklin D. Ultrastructural studies of hematopoietic elements in relation to the myelofibrosis-osteosclerosis syndrome, megakaryocytes and platelets (MMM or MOS). In: Dahlem Workshop on myelofibrosis-osteosclerosis syndrome. Burkhardt R, Conley CL, Lennert K, Adler SS, Pincus T, Till JE, eds. Pergamon Press, Viewerg, Germany-west. 1975: 127-143.
13. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000; 96: 1342-1347.
14. Centurione L, Zingariello M, Bosco D, et al. Increased and pathological emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-Ilow mice. Blood 2004; 104: 3573-3580.
15. Vannucchi AM, Migliaccio AR, Paoletti F, Chagraoui H, Wendling F. Pathogenesis of myelofibrosis with myeloid metaplasma: lessons from mouse models of the disease. Semin Oncol 2005; 32: 365-372.
16. Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995; 86: 4025-4033.
17. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by over expressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996; 88: 402-409.
18. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematol 1997; 98: 1004-1009.
19. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255-2258.
20. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918.
21. Pastore C, Nomdedeu J, Volpe G, et al. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosomes Cancer 1995; 14: 106-111.
22. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98: 96-102.
23. Juneau AL, Kaeler M, Christensen ER, et al. Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. Cancer Genet Cytogenet 1998; 103: 117-123.
24. Boundel M, Sciuccati G, Feliu-Torres A, Pierini A,, Gallo G. Familial idiopathic Myelofibrosis and multiple hemangiomas. Am J Hematol 1998; 59: 175-177.
25. Gilbert HS. Familial myeloproliferative disease. Baillieres Clin Haematol 1998; 11: 849-858.
26. Siitonen T, Savolainen ER, Koistinen P. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Leukemia 1994; 8: 631-637.
27. Nakata Y, Kimura A, Katoh O, et al. e-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995; 91: 661-663.
28. Kimura A, Nakata Y, Katoh O, Hyodo H. c-kit point mutation in patients with myeloproliferative disorders. Leuk Lymphoma 1997; 25: 281-287.
29. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88: 4534-4546.
30. Russel ES. Hereditary anemias of the mouse: a review for geneticists. Adv Genet 1979; 20: 357
31. Besmer P. The kitligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr Biol 1991; 3: 939-946.
32. Gaidano G, Guerrasio A, Serra A, Rege-Cambrin G, Saglio G. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia 1994; 8: S27-S29.
33. Wang JC, Chen C. N-RAS oncogene mutations in patients with agnogenic myeloid metaplasia in leukemic transformation. Leuk Res 1998; 22: 639-643.
34. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000; 96: 3310-3321.
35. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86: 419-431.
36. Zhou W, Toombs CF, Zou T, Guo J, Robinson MO. Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment. Blood 1997; 89: 1551-1559.
37. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998; 160: 691-699.
38. Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997; 99: 739-745.
39. Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1 and TGF-β 1 in the development of myelofibrosis. Blood 2005; 105: 3493-3501.
40. Orkin SH. Transcription factors that regulate lineage decisions. In: Stamatoyannopoulous G, Ed. The molecular basis of blood diseases. Philadelphia PA: WB Saunders. 2000: 80-120.
41. Farina SF, Girard LJ, Vanin EF, Nienhuis AW, Bodine DM. Dysregulated expression of GATA-1 following retrovirus-mediated gene transfer into murine hematopoietic stem cells increases erythropoiesis. Blood 1995; 86: 4124-4133.
42. Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349: 257-260.
43. McDevitt MA, Fujiwara Y, Shivdasani RA, Orkin SH. An upstream, DNAse I hypersensitive region of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice. Proc Natl Acad Sci USA 1997; 94: 7976-7981.
44. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 3965-3973.
45. McDevitt MA, Shivdasani RA, Fujiwara Y, Yang H, Orkin SH. A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA 1997; 94: 6781-6785.
46. Vannucchi AM, Bianchi L, Cellai C, et al. Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(Iow) mice). Blood 2001; 97: 3040-3050.
47. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice). Blood 2002; 100: 1123-1132.
48. Kacena MA, Shivdasani RA, Wilson K, et al. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res 2004; 19: 652-660.
49. Martelli F, Ghinassi B, Panetta B, et al. Variegation of the phenotype induced by the gata-1low mutation in mice of different genetic backgrounds. Blood Aug 18, 2005 [Epub ahead of print].
50. Zetterberg E, Vannucchi AM, Migliaccio AR, et al. Pericyte coverage of abnormal blood vessels in myelofibrosis bone marrows. Blood (Submitted).
51. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997; 90: 4369-4383.
52. Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999; 93: 125-139.
53. Martyre MC, Steunou V, LeBousse-Kerdiles MC, Wietzerbin J. Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis. Blood 2003; 101: 5087-5088.
54. Vannucchi AM, Pancrazzi A, Guglielmelli P, et al. Abnormalities, of GATA-1 in Megakaryocytes from patients with idiopathic myelofibrosis. Am J Path. 2005; 167: 849-858.
55. Thiele J, Lorenzen J, Manich B, Kvasnicka HM, Zirbes TK, Fischer R. Apoptosis (programmed cell death) in idiopathic, (primary) osteo-/ myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis. Acta Haematol 1997; 97: 137-143.
56. Asher E, Payne CM, Bernstein C. Evaluation of cell death in EBV-transformed lymphocytes using agarose gel electrophoresis, light microscopy and electron microscopy. II. Induction of non-classic apoptosis ("para-apoptosis") by tritiated thymidine. Leuk Lymphoma 1995; 19:107-119.
57. Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 2000; 97: 14376-14381.
58. Toki T, Katsuoka F, Kanezaki R, et al. Transgenic expression of BACH1 transcription factor results in megakaryocytic impairment. Blood 2005; 105: 100-108.
59. Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002; 195: 1599-1611.
60. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004; 200: 569-580.
61. Bobik R, Dabrowski Z. Emperipolesis of marrow cells within megakaryocytes in the bone marrow of sublethally irradiated mice. Ann Hematol 1995; 70: 91-95.
62. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148-152.
63. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103: 2480-2489.
64. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994; 88: 9-16.
65. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002; 100: 3495-3503.
66. Chagraoui H, Tulliez M, Smayra T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 2003; 101: 2983-2989.
67. Hilbe W, Dimhofer S, Oberwasserlechner F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004; 57: 965-969.
68. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15: 139-145.
69. Schneider M, Tjwa M, Carmeliet P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 2005; 7: 3-4.
70. Bagley RG, Walter-Yohrling J, Cao X, et al. Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res 2003; 63: 5866-5873.
71. Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000, 157:15-19
72. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
73. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-262.
74. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
75. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+CD133+VEGFR-2+ Endothelial Cells in Myelofibrosis with Myeloid Metaplasia. J Clin Oncol 2005, 23:5688-5695.
76. Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000, 96:3374-3380
77. Thiele J, Rompcik V, Wagner S, Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow. Br J Haematol 1992, 80:227-234
78. Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol 2004, 19:1245-1260
79. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.
80. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
81. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161.
82. Taichman RS, Emerson SG. The role of osteoblasts in the hematopoietic microenvironment. Stem Cells 1998; 16: 7-15.
83. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004; 103: 3258-3264.
84. Greenfield EM, Horowitz MC, Lavish SA. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J Biol Chem 1996; 27: 10984-10989.
85. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000; 106: 1331-1339.
86. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64-71.
87. Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 2003; 102: 1249-1253.
88. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973-981.
89. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694.
90. Lévesque J-P, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-1297.
91. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
92. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-3360.
93. Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B, Papayannopoulou T. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 2002; 99: 44-51.
94. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
95. Papayannopoulou T. Bone marrow homing: the players, the playfield, and their evolving roles. Curr Opin Hematol 2003; 10: 214-219.
96. Lichterfeld M, Martin S, Burkly L, Haas R, Kronenwett R. Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 2000; 110: 71-81.
97. Prosper F, Stroncek D, Verfaillie CM. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor. Blood 1996; 88: 2033-2042.
98. Voermans C, Kooi MLK, Rodenhuis S, van der Lelie H, van der Schoot E, Gerritsen WR. In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood 2001; 97: 799-804.
99. + cells and their transmigration through reconstituted basement membrane. Blood 1999; 93: 3379-3390.
100. Lévesque JP, Hendy J, Winkler IG, Takamatsu Y, Simmons PJ. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 2003; 31: 109-117.
101. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998; 91: 100-110.
102. + cells on vascular endothelium under shear flow. J Clin Invest 1999; 104: 1199-1211.
103. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276: 43503-43508.
104. + cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 3289-3296.
105. Zou Y-R, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function ofthe chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-599.
106. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCLl2 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-196.
107. van Buul JD, Voermans C, van den Berg V, et al. Migration of human hematopoietic progenitor cells across bone marrow endothelium is regulated by vascular endothelial cadherin. J Immunol 2002; 168: 588-596.
108. + cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98: 3249-3255.
109. Xu M, Bruno E, Chao J, et al. The constitutive mobilization of bone marrow repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005; 105: 1669-1705.
110. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001, 98:3249-3255
111. Andreasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol. 2002, 68:189-193
112. Passamonti F, Vanelli L, Malabarba L, et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica 2003, 88:1123-1129
113. Xu M, Bruno E, Chao J, et al. The Constitutive Mobilization of CD34+ Cells into the Peripheral Blood in Idiopathic Myelofibrosis May Be Due to the Action of a Number of Proteases. Blood 2005; 105: 4508-4515.
114. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 2000; 96: 2022-2036.
115. Wiesmann A, Kim M, Georgelas A, et al. Modulation of hematopoietic HSC/ HPC engraftment by transforming growth factor beta. Exp Hematol 2000; 28: 128-139.
116. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119.
117. Christopherson KW 2nd, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 2002; 169: 7000-7008.
118. Christopherson KW 2nd, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003; 101: 4680-4686.
119. Hasselbalch H, Junker P, Horslev-Petersen K, Lisse I, Bentsen KD. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am J Hematol 1990; 33: 18-26.
120. Phillips RL, Ernst RE, Brunk B, et al. The genetic program of hematopoietic stem cells. Science 2000; 288: 1635-1640.
121. Terskikh AV, Miyamoto T, Chang C, Diatchenko L, Weissman IL. Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood 2003; 102: 94-101.
122. Grass JA, Boyer ME, Pal S, Wu J, Weiss MJ, Bresnick EH. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA 2003; 100: 8811-8816.
123. Pal S, Cantor AB, Johnson KD, Moran TB, Boyer ME, Orkin SH, Bresnick EH. Coregulator-dependent facilitation of chromatin occupancy by GATA-1. Proc Natl Acad Sci U. S. A. 2004; 101: 980-985.
124. Migliaccio AR, Jiang Y, Migliaccio G, et al. Transcriptional and posttranscriptional regulation of the expression of the erythropoietin receptor gene in human erythropoietin-responsive cell lines. Blood 1993; 82: 3760-3769.
125. Nijhof W, Wierenga PK, Pietens J, Bloem R. Cell kinetic behaviour of a synchronized population of erythroid precursor cells in vitro. Cell Tissue Kinet 1984; 17: 629-639.
126. Hu M, Krause D, Greaves M, Sharkis S, Dexter M, Heyworth C, Enver T. Multilineage gene expression precedes commitment in the hematopoietic system. Genes Dev 1997; 11: 774-785.
127. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-1312.
128. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation. Cell 1994; 77: 307-316.
129. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythro-poietic anaemia and thrombocytopenia due to an inheredited mutation in GATA 1. Nat Genet 2000; 24: 266-270.
130. Yu C, Niakan KK, Matsushita M, et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FG-1 interation. Blood 2002; 100: 2040-2045.
131. Freson K, Devriendt K, Matthijs G, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 2001; 98: 85-92.
132. Mehaffey MG, Newton AL, Gandhi MJ, et al. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 2001; 98: 2681-2688.
133. Harigae H, Xu G, Sugawara T, et al. The GATA-1 mutation in an adult patient with acute megakaryoblastic leukaemia not accompanying Down syndrome. Blood 2004; 103: 3242-3243.
134. Bobel GA, Simon MC, Orkin SH. Rescue of GATA-1-deficent embryonic stem cells by heterologous GATA-binding proteins. Mol Cell Biol 1995; 15: 626-633.
135. Shimizu R, Takahashi S, Ohneda K. In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO J 2001; 20: 5220-5260.
136. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37: 613-619.
137. Migliaccio AR, Rana RA, Sanchez M, et al. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J Exp Med 2003; 197: 281-296.
138. Shimizu R, Kuroha T, Ohneda O, et al. Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol 2004; 24: 10814-10825.
139. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001; 98: 586-593.
140. Guardiola P, Anderson JE, Gandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831-2838.
141. Deeg HJ, Appelbaum FR. Stem-cell transplantation for myelofibrosis. N Engl J Med 2001; 344: 775-776.
142. Deeg HJ, Guardiola P. Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. Int J Hematol. 2002; 76: 29-34.
143. Hessling J, Kroger N, Werner M, et al. Dose-reduced conditioning regimen followed by allergenic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769-772.
144. Hertenstein B, Guardiola P, Finke J, et al. Non-myeloablative (NMA) stem cell transplantation (SCT) for myeloid metaplasia with myelofibrosis (MMM)-A survey from the chronic leukemia working party of the EBMT. Blood 2002; 100(Suppl): 70a.
145. Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690-697
146. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol 2005 (In press).
147. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003; 32: 35-40.
148. Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34: 807-813.
149. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001; 98: 3261-3273.
150. Persons DA, Paulson RF, Loyd MR, et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet 1999; 23: 159-165.